美股異動 | 黑莓大升14% Q4每股虧損低於市場預期
格隆匯3月31日丨黑莓升14.75%,報4.59美元,總市值27億美元。黑莓2023年Q4財報實現營收1.51億美元,前值為1.85億美元,預期值為1.567億美元,比市場預期低3.61%;每股虧損0.02美元,前值為0.01美元,預期值為虧損0.07美元,低於市場預期71.43%。此外,黑莓宣佈,已達成協議,將其非核心專利和專利申請出售給Key Patent Innovations Limited(KPI)新成立的子公司Malikie Innovations Limited(Malikie),交易產生的現金收益及潛在的未來特許權使用費總額高達9億美元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.